What happened
Wiley and IQVIA released a cross-sector intelligence report synthesizing insights from an invitation-only two-day summit (May 2026) with 25+ senior leaders from pharma R&D, academic medicine, health systems, technology, and publishing. The report identifies a critical gap between AI's technical capability and the health system's ability to absorb it: 'AI is accelerating every stage of the journey from scientific discovery to patient benefit—but acceleration at one stage can create fracture at the next.' The report maps findings across four stages of the science-to-patient value chain (Discovery & Early Research, Clinical Development & Evidence Generation, Validation & Dissemination, Real-World Adoption & Patient Impact) and identifies five high-potential directions for ecosystem evolution: decision-first discovery, structured negative data sharing, AI agents for patients, curated aggregation of scholarly and real-world evidence, and continuous learning loops feeding real-world evidence back upstream.
Why it matters
This report reframes AI governance in healthcare from isolated model deployment to systemic value-chain integration. For executives in pharma, health systems, and AI companies, it surfaces the organizational and structural impediments (incentive misalignment, publishing delays, infrastructure fragmentation) that prevent AI from reaching patients at speed—informing both strategy and capital allocation in healthcare AI initiatives.
Action needed
Executive teams in pharma and health systems should map their current AI deployments against the report's four-stage framework to identify where acceleration in one stage is creating bottlenecks elsewhere; identify where incentive misalignment is blocking progress; and design cross-functional accountability structures to govern the science-to-patient continuum as a single system, not as four separate value-chain layers.